Author:

Keywords:

buprenorphine, cancer pain, palliative, transdermal, Administration, Cutaneous, Adult, Analgesics, Opioid, Buprenorphine, Female, Humans, Male, Neoplasms, Pain, Pain Management, Pain Measurement, Palliative Care, Pilot Projects, Prospective Studies, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, DOUBLE-BLIND, ORAL MORPHINE, EFFICACY, CARE, TOLERABILITY, MULTICENTER, FENTANYL, SAFETY, 1101 Medical Biochemistry and Metabolomics, 3202 Clinical sciences

Abstract:

Despite guidelines and recommendations, a large proportion of patients with cancer still have inadequate pain control. Transdermal opioid administration can overcome problems such as swallowing and compliance, because only one application every three days is needed. Transdermal buprenorphine was documented to provide effective pain relief in cancer and non-cancer patients. A ceiling effect was described in animals at supratherapeutic dose levels.